Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
INTRODUCTION. IgG4-related disease (ER-IgG4) is a multiorgan fibroinflammatory pathology of unknown origin that mimics malignant, infectious, and inflammatory disorders. The criteria of the American College of Rheumatology and the European League against Rheumatism 2019 are useful for the differential diagnosis of this disease when there is no evidence of immunoglobulin G4 in blood. CLINICAL CASE. 45-year-old male patient, born in Ambato-Ecuador, with admission in November 2017, in the emergency room of the Hospital de Especialidades Carlos Andrade Marín, with the presence of cough with mild hemoptysis, fever, asthenia, weight loss and hyporexia of two weeks of evolution. Multiple tests were performed, after observing interstitial pulmonary infiltrates, with elevated serum immunoglobulin G, negative for malignancy; immunoglobulin G4-related disease was suspected. Studies were extended to rule out other more prevalent pathologies whose differential is paramount. Treatment with prednisone and mycophenolate was started with good clinical response; for two years. DISCUSSION. The scientific evidence recorded that the most important finding in immunoglobulin G4-related disease was an increase in its serum levels. Recurrence of the disease in an affected organ or the appearance of a new involved organ could have led to the diagnosis in the presented case. CONCLUSION. Immunoglobulin G4-related disease, being a heterogeneous, immune-mediated pathology, by simulating other conditions may delay diagnosis; a high clinical suspicion should be maintained if, when other infectious, autoimmune and/or neoplastic processes are excluded, there is evidence of multiorgan fibrosclerosing pathology without established cause.
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012; 366 (6): 539–51. Available from: https://pubmed.ncbi.nlm.nih.gov/22316447/
Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012; 25: 1181–92. Available from: https://pubmed.ncbi.nlm.nih.gov/22596100/
Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet 2015; 385: 1460–71. Available from: https://pubmed.ncbi.nlm.nih.gov/25481618/
Ardila-Suarez O, Abril A, Gómez-Puerta JA. Enfermedad relacionada con IgG4: revisión concisa de la literatura. Reum Clin Reum Clin [Internet]. 2017;13(3):160–6. Available from: https://www.sciencedirect.com/science/article/pii/S1699258X16300535?via%3Dihu
Yadlapati S, Verheyen E, Efthimiou P. IgG4-related disease: a complex under-diagnosed clinical entity.Rheumatol Int. 2018;38(2):169-177. Available from: https://www.google.com/search?q=Yadlapati+S%2C+Verheyen+E%2C+Efthimiou+P.+IgG4-related+disease%3A+a+complex+under-diagnosed+clinical+entity.Rheumatol+Int.+2018%3B38(2)%3A169-177&rlz=1C1CHBD_esEC842EC842&oq=Yadlapati+S%2C+Verheyen+E%2C+Efthimiou+P.+IgG4-related+disease%3A+a+complex+under-diagnosed+clinical+entity.Rheumatol+Int.+2018%3B38(2)%3A169-177&aqs=chrome..69i57.1039j0j7&sourceid=chrome&ie=UTF-8
Perugino CA, Mattoo H, Mahajan VS, et al. Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies. Arthritis Rheumatol 2017; 69: 1722–32. Available from: https://pubmed.ncbi.nlm.nih.gov/28575535/
Brito-Zerón P, Bosch X, Ramos-Casals M, Stone JH. IgG4-related disease: Advances in the diagnosis and treatment. Best Pract Res Clin Rheumatol. 2016 ;30(2):261-278. Available from:https://pubmed.ncbi.nlm.nih.gov/27886799/
Okazaki K, Umehara H. Current Concept of IgG4-Related Disease.Curr Top Microbiol Immunol. 2017; 401:1-17. Available from: https://pubmed.ncbi.nlm.nih.gov/28091932/
Okazaki K, Uchida K. Current Concept of Autoimmune Pancreatitis and IgG4-related Disease. Am J Gastroenterol. 2018;113(10):1412-1416. Available from: https://pubmed.ncbi.nlm.nih.gov/30002467/
Kawa S. Current Concepts and Diagnosis of IgG4-Related Pancreatitis (Type 1 AIP). Semin Liver Dis. 2016;36(3):257-73. Available from:https://pubmed.ncbi.nlm.nih.gov/27466795/
Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T et.al. Comprehensive diagnostic criteria for IgG4-related disease. Mod Rheumatol. 2012;22(1):21-30. Avaialble from: https://pubmed.ncbi.nlm.nih.gov/22218969/
Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino et, al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012 Sep;25(9):1181-92. Available from:https://pubmed.ncbi.nlm.nih.gov/22596100/
Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Stone JH, et al. The 2019 preliminary American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-related disease. Arthritis & Rheumatology. Vol. 72, No. 1, Jan 2020. Pp. 7-19. Available from: https://www.rheumatology.org/Portals/0/Files/Classification-Criteria-IgG4-Related-Disease.pdf
Kamizawa T, Zen Y, Pillay S, Stone JH. IgG4-related disease. Lancet [Internet]. 2015;385(9976):1460–71. Available from:https://pubmed.ncbi.nlm.nih.gov/25481618/
Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, et al. IgG4-related disease: Dataset of 235 consecutive patients. Med (United States). 2015;94(15): e680 1–8. Available from: https://pubmed.ncbi.nlm.nih.gov/25881845/
Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S SJ. IgG4-Related Disease: Baseline clinical and laboratory features in 125 patients with biopsy-proven disease. Arthritis Rheumatol. 2015;67(9):2466–75. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621270/
Wallace ZS, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum [Internet]. 2014 Jun [cited 2019 Jul 8];43(6):806–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24513111
Johnston J, Allen JE. IgG4-related disease in the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2018;26(6):403–8. Available from: https://pubmed.ncbi.nlm.nih.gov/30234659/
Kamisawa T, Zen Y, Nakazawa T, Okazaki K. Advances in IgG4-related pancreatobiliary diseases. Lancet Gastroenterol Hepatol [Internet]. 2018;3(8):575–85. Available from: https://pubmed.ncbi.nlm.nih.gov/30047448/
Baltaxe E, Shulimzon T, Lieberman S, Rozenman J, Perelman M, Segel MJ. Enfermedad pulmonar relacionada con IgG4 - Tres casos no tratados con resultado benigno. Arch Bronconeumol. 2015;52(1): e1–3. Available from: https://www.archbronconeumol.org/es-enfermedad-pulmonar-relacionada-con-igg4-articulo-S0300289615003257
Idoyaga P, Fielli M, González A, Ferreyra Ñ, Fernández M, Crevena G. Casuística: Enfermedad Pulmonar intersticial por IgG4. 2018;78(6):449–52. Available from: http://www.scielo.org.ar/pdf/medba/v78n6/v78n6a12.pdf
Campbell SN, Rubio E, Loschner AL. Clinical review of pulmonary manifestations of IgG4-related disease. Ann Am Thorac Soc. 2014 Nov;11(9):1466–75. Available from: https://pubmed.ncbi.nlm.nih.gov/25422997/
Wallace ZS, Naden RP, Chari S, Choi HK, Della.Torre E, Dicaire JF, et al. The
American College of Rheumatology/European League Against Rheumatism
classification criteria for IgG4-related disease. Ann Rheum Dis.2020 Jan;72(1):7-19. Available from: https://pubmed.ncbi.nlm.nih.gov/31793250/
Della-Torre E, Stone JH. “How I manage” IgG4-Related Disease.J Clin Immunol 2016; 36(8): 1-10. Available from: https://www.researchgate.net/publication/309412049_How_I_manage_IgG4-Related_Disease
Brito-Zeron P, Kostov B, Bosch X, Acar-Denizli N, Ramos-Casals M, Stone JH. Therapeutic approach to IgG4-related disease: a systematic review. Medicine Jun 2016; 95 (26): e4002. Available from: https://pubmed.ncbi.nlm.nih.gov/27368010/
Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther 2018; 20 (1): 65. Available from: https://pubmed.ncbi.nlm.nih.gov/29636109/
Wu Q, Chang J, Chen H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. Int J Rheum Dis 2017; 20(5): 639–46. Available from:https://pubmed.ncbi.nlm.nih.gov/28556584/
Yunyun F, Yu C, Panpan Z, et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep 2017; 7 (1): 6195. Available from: https://pubmed.ncbi.nlm.nih.gov/28733656/
Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatol 2019; 58 (1): 52–60. Available from: https://pubmed.ncbi.nlm.nih.gov/30124952/
Zhang W, Stone J. Management of IgG4-related disease. Lancet Rheumatol 2019; 1: e55–65. Available from: https://www.researchgate.net/publication/335539754_Management_of_IgG4-related_disease
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.
